| Index | — | P/E | — | EPS (ttm) | -1.96 | Insider Own | 2.46% | Shs Outstand | 53.08M | Perf Week | -11.44% |
| Market Cap | 497.36M | Forward P/E | — | EPS next Y | -0.29 | Insider Trans | -2.06% | Shs Float | 12.60M | Perf Month | -37.91% |
| Enterprise Value | 290.36M | PEG | — | EPS next Q | -0.15 | Short Float | 40.43% | Perf Quarter | -27.92% | ||
| Income | -24.00M | P/S | 24.87 | EPS this Y | — | Short Ratio | 24.13 | Perf Half Y | -37.41% | ||
| Sales | 20.00M | P/B | 2.31 | EPS next Y | — | ROA | -9.07% | Short Interest | 5.09M | Perf YTD | 559.86% |
| Book/sh | 4.05 | P/C | 2.13 | EPS next 5Y | — | ROE | -21.82% | 52W High | 17.25 -45.68% | Perf Year | 574.10% |
| Cash/sh | 4.39 | P/FCF | — | EPS past 3/5Y | — | ROIC | -9.23% | 52W Low | 0.88 966.47% | Perf 3Y | -3.40% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | — | Volatility | 7.12% 9.37% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 14.52 | EPS Y/Y TTM | — | Oper. Margin | -113.28% | ATR (14) | 1.03 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 9.55 | Sales Y/Y TTM | — | Profit Margin | -114.48% | RSI (14) | 30.77 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 9.55 | EPS Q/Q | 77.78% | SMA20 | -19.83% | Beta | 2.00 | Target Price | 37.33 |
| Payout | 0.00% | Debt/Eq | 0.12 | Sales Q/Q | — | SMA50 | -31.75% | Rel Volume | 1.26 | Prev Close | 9.55 |
| Employees | 109 | LT Debt/Eq | 0.04 | Earnings | Mar 03 | SMA200 | -18.01% | Avg Volume | 216.95K | Price | 9.37 |
| IPO Date | Sep 29, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 77.78% 46.80% | Net Debt/EBITDA | — | Volume | 272,626 | Change | -1.88% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Reiterated | Jefferies | $31 | |
| Sep-08-26 | Reiterated | Loop Capital Markets | ||
| May-28-26 | Initiated | Oppenheimer | Outperform | $32 |
| Apr-20-26 | Reiterated | HC Wainwright & Co. | Buy | $16 → $20 |
| Feb-13-26 | Upgrade | HC Wainwright & Co. | Neutral → Buy | $9.00 → $16 |
| Jun-02-25 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| Sep-04-24 | Initiated | H.C | Buy | $9.00 |
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20 | 5 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | |
| Gross Profit | 20 | 5 | 0 | 0 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10 | 8 | 9 | 15 | — | — | — | — | |
| Research and Development | 32 | 33 | 45 | 58 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | 0 | — | — | — | — | |
| Operating Income | -22 | -36 | -53 | -73 | — | — | — | — | |
| Interest Expense | 0 | 1 | 2 | 1 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 2 | 3 | -36 | — | — | — | — | |
| Net Income Before Taxes | -24 | -36 | -52 | -109 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -24 | -36 | -52 | -109 | — | — | — | — | |
| Net Income From Continuing Operations | -24 | -36 | -52 | -109 | — | — | — | — | |
| Net Income | -24 | -36 | -52 | -109 | — | — | — | — | |
| EPS (Recurring) | -1.96 | -3.33 | -4.89 | -15.42 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.96 | -3.33 | -4.89 | -15.42 | — | — | — | — | |
| EPS (Diluted) | -1.96 | -3.33 | -4.89 | -15.42 | — | — | — | — | |
| EBITDA | -22 | -33 | -48 | -106 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.50 | 3.12 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -110.00 | -720.00 | — | — | — | — | — | — | |
| Net Margin | -120.00 | -720.00 | — | — | — | — | — | — | |
| Shares Outstanding | 16 | 11 | 11 | 7 | — | — | — | — | |
| Market Capitalization | 150 | 16 | 30 | 63 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ji Ping | Director | Sep 30 '26 | Sale | 15.99 | 10,000 | 159,900 | 121,453 | Oct 01 |
| Ji Ping | Director | Sep 29 '26 | Sale | 15.77 | 214 | 3,375 | 131,453 | Oct 01 |
| Ji Ping | Director | Sep 22 '26 | Sale | 16.63 | 5,000 | 83,150 | 131,667 | Sep 24 |
| Ye Xiaofeng | CFO | Aug 26 '26 | Sale | 14.25 | 5,667 | 80,755 | 147,757 | Aug 26 |
| Ye Xiaofeng | CFO | Aug 24 '26 | Sale | 13.98 | 6,000 | 83,880 | 153,424 | Aug 26 |
| LU YANG | CEO | May 13 '26 | Sale | 13.18 | 10 | 132 | 99,990 | May 21 |
| CONSIDINE TERRY | Chairman & CEO | Apr 15 '08 | Option Exercise | 19.38 | 300,000 | 5,812,500 | 450,000 | Apr 17 |
| RHODES THOMAS L | Director | Apr 03 '08 | Option Exercise | 19.38 | 100,000 | 1,937,500 | 185,717 | Apr 07 |
| BLATZ ROBERT G | President and COO | Apr 26 '06 | Sale | 26.95 | 750 | 20,213 | 240,287 | Apr 28 |
| BLATZ ROBERT G | President and COO | Apr 24 '06 | Sale | 26.94 | 500 | 13,470 | 241,037 | Apr 25 |
| BLATZ ROBERT G | President and COO | Apr 21 '06 | Sale | 27.02 | 500 | 13,510 | 241,537 | Apr 24 |
| BLATZ ROBERT G | President and COO | Apr 20 '06 | Sale | 26.95 | 500 | 13,475 | 242,037 | Apr 21 |
| BLATZ ROBERT G | President and COO | Apr 19 '06 | Sale | 27.05 | 1,050 | 28,405 | 242,537 | Apr 21 |
| BLATZ ROBERT G | President and COO | Apr 17 '06 | Sale | 27.24 | 250 | 6,810 | 243,587 | Apr 19 |
| BLATZ ROBERT G | President and COO | Apr 13 '06 | Sale | 27.23 | 250 | 6,807 | 243,837 | Apr 14 |